sotalol / Generic mfg. - LARVOL DELTA

Metastatic Misroute: Primary Pancreatic Neuroendocrine Tumor With Intracardiac Metastasis (ACG 2026) - "She was treated with capecitabine-temozolomide, though capecitabine was discontinued due to chest pain. Follow-up imaging demonstrated progression with gastric invasion despite therapy and lutetium Lu-177 dotatate was initiated...She developed recurrent ventricular arrhythmias, including torsades de pointes during amiodarone infusion requiring transition to lidocaine, mexiletine, sotalol, and metoprolol...Figure: Cardiac MR was done and showed 3 abnormally enhancing masses in the left ventricle. Figure: CT revealing large pancreatic NET."

Metastases • Cardiovascular • Diabetes • Gastrointestinal Disorder • Gastrointestinal Neuroendocrine Tumor • Metabolic Disorders • Neuroendocrine Tumor • Oncology • Ovarian Cancer • Solid Tumor • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Pregnancy-associated idiopathic ventricular arrhythmia: Serial electrocardiographic evolution during pregnancy and postpartum. (PubMed, J Electrocardiol) - "Sotalol, introduced with serial QT monitoring, was followed by complete symptomatic and Holter suppression. One month postpartum, asymptomatic ventricular arrhythmia recurred off therapy, then resolved spontaneously by three months. Serial monitoring illustrates marked pregnancy-related variability and the potential dissociation between symptoms and arrhythmic burden."

Journal • Cardiovascular • Ventricular Tachycardia

ReCAST AF: Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation (clinicaltrials.gov) - P4 | N=988 | Recruiting | Sponsor: Universitaire Ziekenhuizen KU Leuven | Not yet recruiting ➔ Recruiting

Enrollment open • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease

Comparative analysis of infarct-reducing properties of ß1 -, ß2 -, and ß3 -adrenergicreceptor ligands in ischemia and reperfusion of the heart. (PubMed, Pharmacology) - "β 1 -AR blockade increases cardiac tolerance to I/R in vivo. β 2 -AR blockade and β 2 - AR stimulation do not affect cardiac resistance to I/R in vivo. β 3 -AR blockade does not affect cardiac resistance to I/R in vivo."

Journal • Anesthesia • Cardiovascular • Myocardial Infarction

Beyond pooled analysis: sex-specific cardiovascular adverse event reporting signals with antiarrhythmic drugs in FAERS. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Sex-stratified analysis uncovered "hidden" associations undetected in pooled data, including propafenone-QT prolongation in men and amiodarone-QT prolongation in women. Adverse event profiles were often drug-specific and opposing: cardiogenic shock showed higher reporting odds among males for sotalol, whereas flecainide showed higher reporting odds in females...Sex-specific CV-AE profiles reporting patterns are often masked in pooled analyses, underscoring the need for sex-stratified pharmacovigilance to guide personalized antiarrhythmic therapy. The identified associations should be considered hypothesis-generating and require validation in datasets with richer clinical information."

Adverse events • Journal • Retrospective data • Cardiovascular

Comparative Effectiveness of Propranolol versus Flecainide/Sotalol for Supraventricular Tachycardia Prophylaxis in Children Aged 1-17 Years: A Multicenter Retrospective Cohort Study (AHA 2026) - "Abstract is embargoed at this time."

HEOR • Retrospective data • Cardiovascular • Ventricular Tachycardia

Association of common QT-prolonging medications with arrhythmic risk in patients with bundle branch block: A stratified cohort analysis in left bundle branch block vs. right bundle branch block phenotypes. (PubMed, Heart Lung) - "Common non-cardiac QT-prolonging medications were not associated with increased risk in patients with BBB, even with prolonged QTc. The divergence between composite and sensitivity results for amiodarone highlights the influence of confounding by indication. Medication alerts should incorporate stratification by drug class rather than QTc alone."

Journal • Cardiovascular • CNS Disorders • Congestive Heart Failure • Critical care • Heart Failure

One-year outcomes of rhythm control strategies for atrial fibrillation among patients with cardiac amyloidosis and heart failure (ESC 2026) - "Objective We compared clinical outcomes between catheter ablation and antiarrhythmic drug therapy for atrial fibrillation in patients with amyloidosis and heart failure Methods We conducted a retrospective cohort study using TriNetX Research Network, identifying 1,541 patients who underwent catheter ablation and 8,677 patients treated with antiarrhythmics (amiodarone, sotalol, dofetilide, dronedarone) for atrial fibrillation with documented amyloidosis and heart failure. Stroke rates were similar (6.9% vs 8.2%, p=0.232). Catheter ablation was associated with higher cardioversion requirements (22.1% vs 14.1%, p<0.001) Conclusion In patients with cardiac amyloidosis, heart failure, and atrial fibrillation, catheter ablation was associated with decreased mortality compared to antiarrhythmic drugs, along with significantly fewer heart failure events and hospitalizations."

Clinical • Atrial Fibrillation • Cardiac Amyloidosis • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Ventricular Tachycardia

Pharmacologic and non-pharmacologic interventions for preventing postoperative atrial fibrillation in cardiac surgery: systematic review and network meta-analysis (ESC 2026) - "Across various beta-blocker types, sotalol demonstrated higher robustness in the prevention of POAF. ConclusionsCombination therapies were found to be superior to monotherapy for the prevention of POAF.Among single-agent interventions, amiodarone and beta-blockers remained the most robust options, demonstrating comparable prophylactic efficacy. Regarding non-pharmacological strategies, the most favorable outcomes were atrial pacing combined with amiodarone and biatrial pacing alone."

Retrospective data • Review • Surgery • Atrial Fibrillation • Cardiovascular

Cryo-InitialAF: Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation (clinicaltrials.gov) - P=N/A | N=320 | Completed | Sponsor: Ruijin Hospital | Recruiting ➔ Completed | Trial completion date: Jan 2026 ➔ Aug 2025

Trial completion • Trial completion date • Atrial Fibrillation • Cardiovascular

A meta-analysis of randomized controlled trials on atenolol's impact on postoperative atrial fibrillation in adults undergoing cardiac surgery. (PubMed, Medicine (Baltimore)) - "Atenolol did not demonstrate superiority over sotalol in reducing POAF (RR, 2.39; 95% CI: 1.41-4.04; P = .001) with moderate heterogeneity (I2 = 40%; P = .19). Furthermore, no significant difference was observed between atenolol and the control group (comprising propafenone, metoprolol, nebivolol, and digoxin) in the prevention of POAF (RR, 1.28; 95% CI: 0.76-2.16; P = .35) with moderate heterogeneity (I2 = 43%; P = .15). Recent studies suggest that atenolol could be a safe and effective intervention for the prevention of POAF in adult patients undergoing CS."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone. (PubMed, Diabetes Obes Metab) - "Initiation of amiodarone in patients receiving sulfonylureas was associated with a higher risk of hypoglycemia compared with other antiarrhythmics. Given the continued use of sulfonylureas in diabetes care, this finding highlights the need for caution and close monitoring during their concomitant use with amiodarone."

Journal • Cardiovascular • Diabetes • Hypoglycemia • Metabolic Disorders • Severe Hypoglycemia • Type 2 Diabetes Mellitus

Metagenomic insights into microbial drivers of organic micropollutant removal in wastewater-impacted riverbank filtration. (PubMed, Water Res) - "Sediment preferentially attenuated hydrophilic or charged compounds, including lidocaine, amantadine, and sotalol, whereas soil contributed more strongly to the attenuation of naproxen, atenolol, and losartan. These findings indicate that sediment and soil develop complementary microbial functional potentials that may support compound-specific OMP attenuation. This study provides a mechanistic basis for optimizing sediment-soil configurations in wastewater-impacted RBF systems and for improving nature-based barriers against diverse OMP mixtures."

Journal

Development and validation of a green dispersive liquid-liquid microextraction-LC-MS/MS method for sotalol quantification in human plasma using central composite design optimization and pharmacokinetic application. (PubMed, Sci Rep) - "Chromatographic separation was achieved on a Poroshell 120 EC-C18 column (100 × 2.1 mm, 2.7 μm) with 4-min isocratic elution, and quantification employed MRM transitions m/z 273.1→255.1 for sotalol and m/z 267.2→145.1 for atenolol internal standard in positive ESI mode. Preliminary pharmacokinetic application in healthy volunteers following single oral 80 mg sotalol administration yielded Cmax 701 ± 53.8 ng/mL, t½ 10.1 ± 1.0 h, and AUC0→∞ 11,713 ± 1,345 ng·h/mL, broadly consistent with published literature values, supporting method applicability for therapeutic drug monitoring. Multi-metric sustainability assessment encompassing AGSA-prep (64/100), AGSA (65.28/100), CaFRI (69/100), BAGI (75.0/100), CACI (69/100), AMRI (71/100), and WECA (81%) demonstrated improved environmental performance relative to conventional extraction approaches, providing comprehensive sustainability characterization of the developed method."

Journal • PK/PD data

A scoping review of the evidence supporting antiarrhythmic use after paediatric cardiac surgery. (PubMed, Cardiol Young) - "Although antiarrhythmics are commonly used in children after cardiac surgery, randomised trials with standardised endpoints to guide choice of therapy are lacking. Pragmatic trials to generate real-world data should be considered to further evaluate the safety and efficacy of various antiarrhythmics in this population."

Journal • Review • Cardiovascular • Pediatrics

Neuronal safety of Kv11.1 blockers: Patch-clamp and in vitro evaluation with physiologically based pharmacokinetic (PBPK) modeling. (PubMed, Toxicol Rep) - "Here, we investigated Sotalol, Ibutilide, and Amiodarone, three clinically used Kv11.1 active compounds with distinct lipophilicity profiles, using an integrated strategy that combines whole-cell patch-clamp electrophysiology, cell viability assays, and physiologically based pharmacokinetic (PBPK) modeling in neuron-like SH-SY5Y cells, a human model widely used for neurotoxicity and ion-channel studies. Amiodarone's high lipid solubility drives persistent intracellular retention and cytotoxic morphology, while Ibutilide primarily exerts transient electrophysiological effects. This integrated PBPK-in-vitro framework provides a mechanistic basis for differentiating CNS risk among antiarrhythmics and highlights lipophilicity and broad ion channel activity as key determinants of neuronal safety."

Journal • PK/PD data • Preclinical

Meta-analysis of the safety of outpatient Sotalol initiation in clinical practice. (PubMed, Indian Pacing Electrophysiol J) - "In carefully selected patients, the initiation of sotalol in an outpatient setting appears to be safe and associated with no significant adverse events. However, the current evidence is limited to a small number of observational cohorts, and large randomized controlled trials are warranted to establish the safety and efficacy of outpatient sotalol initiation."

Journal • Retrospective data • Review • Atrial Fibrillation • Cardiovascular

Intracardiac adenosine triphosphate for cardioversion of supraventricular tachycardia in a hydropic foetus: a case report. (PubMed, Eur Heart J Case Rep) - "After combined transplacental therapy with digoxin and sotalol, the foetal tachycardia remained uncontrolled, with progressive hydrops and deteriorating cardiac function. Intracardiac ATP administration offers a last-resort salvage therapy for terminating recalcitrant SVT with foetal hydrops, which should be reserved for highly selected patients and performed at specialized centres. The larger studies with longer follow-up are needed to validate this procedure's efficacy and safety."

Journal • Cardiovascular • Ventricular Tachycardia

Contemporary Management of Fetal Sustained Supraventricular Tachycardia guided by Prenatal Echocardiography. (PubMed, Indian Pacing Electrophysiol J) - No abstract available

Journal • Cardiovascular • Ventricular Tachycardia

Source-sink dynamics of WADA-prohibited compounds in coastal urban aquatic environments: From WWTP to bay. (PubMed, J Environ Manage) - "Four β-blockers (bisoprolol, metoprolol, propranolol, and sotalol), cocaine, and furosemide were quantified throughout the continuum, alongside CAF and NCT...As a sink, surface sediment in the bay retained only 10 WADA-prohibited compounds across 4 seasonal sampling events, including fentanyl and betaxolol, which were below quantification limits in water samples, likely due to particulate-bound transport and sedimentation. Gender differences on consumption patterns might also influence environmental loadings of WADA-prohibited compounds, in contrast to CAF (with comparable coffee consumption between male and female populations) and NCT (with male-biased smoking prevalence) in the region. This catchment-based study provides a comprehensive understanding of the environmental behaviors of the WADA-prohibited compounds within an urban aquatic system."

Journal

When Rhythm Control Backfires: A Case of Severe QT Prolongation and Polymorphic Ventricular Tachycardia Following Dual Antiarrhythmic Therapy. (PubMed, Cureus) - "We report a case of life-threatening QT prolongation and polymorphic ventricular tachycardia resulting from concurrent sotalol and amiodarone therapy without appropriate washout. Overdrive pacing remains an effective temporizing measure for drug-induced torsades de pointes. Clinicians must be highly cautious while using multiple QT-prolonging agents, particularly in elderly patients with multiple comorbidities."

Journal • Atrial Fibrillation • Cardiovascular • Ventricular Tachycardia

Multi-Center Catalytic Oxidation of the Sotalol Drug Adsorbed on Gold Nanoparticles. (PubMed, Molecules) - "The influence of surface ligands on sotalol conversion was studied using gold nanoparticles coated with thiols, surfactants, and polyelectrolytes. Based on comprehensive data, the mechanism of gold-nanoparticle-assisted multicenter oxidation of sotalol is proposed."

Journal

Shark pedicle island flap for basal cell carcinoma of the perialar zone of the nose: photoxicity and photocarcinogenicity mediated by the intake of potentially nitrosamine contaminated drugs  -a possible new explanation for the skin cancers pathogenesis (EADV-Sp 2026) - "Results We inform about another polymedication intake in a patient with arterial hypertension and diabetes mellitus, which includes the following medications: gliclazide 60 mg once daily and metformin hydrochloride 850 mg once daily, both since 24 years ; sotalol hydrochloride 80 mg since 2 years; bisoprolol fumarate 5 mg since 17 years; candesartan cilexetil/hydrochlorothiazide 16 mg/ 12.5 mg since 2 years; and lercanidipine hydrochloride 20 mg also since 2 years. This article focuses on the possible role of drug-mediated photo nitrosogenesis/ carcinogenesis of skin cancer by briefly reviewing and analyzing the available literature to date. Figure 3: 1 month follow-up"

Basal Cell Carcinoma • Diabetes • Genetic Disorders • Metabolic Disorders • Non-melanoma Skin Cancer • Oncology • Pulmonary Arterial Hypertension • Skin Cancer

Comparative effectiveness of existing medical therapy for atrial fibrillation in hypertrophic cardiomyopathy (AF-HCM) (HEART FAILURE 2026) - "Patients were grouped by post-DCCV outpatient therapy: amiodarone, non-amiodarone AADs (sotalol, dofetilide, dronedarone), or non-AAD therapy (e.g., beta-blockers, calcium channel blockers). Short-term AF recurrence on non-ablative therapy is high, regardless of therapeutic strategy. Amiodarone and non-AAD strategies were more frequent in patients with smaller atria and lower prevalence of prior AF compared to non-amiodarone AADs, reflecting use later in disease course. Use of amiodarone as often as non-AADs in earlier AF-HCM may reflect a preference for immediate stabilization, followed by other AADs with fewer long-term side effects, especially in inpatient settings."

HEOR • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Catheter Ablation Versus Antiarrhythmic Drugs in the Management of Ventricular Tachycardia in Ischemic Cardiomyopathy: An Updated Systematic Review and Meta-analysis. (PubMed, Cardiol Rev) - "In the AAD group, amiodarone and sotalol were used in 60% and 40% of patients, respectively. No significant differences were observed in all-cause mortality, appropriate implantable cardioverter-defibrillator shocks, or VT storm. In patients with ischemic cardiomyopathy and VT, CA reduces arrhythmic events and treatment-related adverse events compared with AAD therapy, although a survival benefit remains unproven."

Journal • Retrospective data • Cardiomyopathy • Cardiovascular • Ventricular Tachycardia